Liquid chromatographic determination of Indolidan (cas 100643-96-7) and its dehydro metabolite in plasma
-
Add time:08/06/2019 Source:sciencedirect.com
A method is described for the determination of Indolidan (cas 100643-96-7) and its dehydro metabolite in human plasma. Two procedures are given, one manual and one which is semi-automated by use of the Varian AASP® (Automated Analytical Sample Processor). The method involves solid-phase extraction to isolate the drug, metabolite, and an internal standard from plasma. The manual procedure requires elution of the analytes from the extraction column with methanol, evaporation of the methanol to dryness, and reconstitution in mobile phase prior to injection into a reversed-phase liquid chromatographic system. Using the AASP® (semi-automated procedure), the analytes are eluted from the extraction column directly into the chromatographic system, resulting in substantial savings in sample preparation time. The limit of detection for both drug and metabolite is 0.25 ng/ml in plasma. Detection was made by ultraviolet absorbance, using wavelength programming to optimize the sensitivity of the assay for each compound.
We also recommend Trading Suppliers and Manufacturers of Indolidan (cas 100643-96-7). Pls Click Website Link as below: cas 100643-96-7 suppliers
Prev:Cardiovascular and adrenal proliferative lesions in Fischer 344 rats induced by long-term treatment with type III phosphodiesterase inhibitors (postive inotropic agents), isomazole and Indolidan (cas 100643-96-7)
Next:Coronary Artery Toxicity in Beagle Dogs Given Indolidan (cas 100643-96-7), a Type III Phosphodiesterase Inhibitor) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Coronary Artery Toxicity in Beagle Dogs Given Indolidan (cas 100643-96-7), a Type III Phosphodiesterase Inhibitor08/07/2019
- Cardiovascular and adrenal proliferative lesions in Fischer 344 rats induced by long-term treatment with type III phosphodiesterase inhibitors (postive inotropic agents), isomazole and Indolidan (cas 100643-96-7)08/05/2019